Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria
Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the tolerability and pharmacokinetics of
Sevuparin/DF02 when administered as an i.v. infusion in combination with Malanil®
(atovaquone/proguanil) as anti-malarial treatment in subjects affected with uncomplicated
malaria. The study will also assess the potential of Sevupatin/DF02 to reduce infected
erythrocyte sequestration and rosette formation.
The study consists of a dose escalation part (part 1) followed by an open labelled,
randomized comparison of treatment with Sevuparin/DF02 and Malanil® versus Malanil® alone
(part 2).